ArticlePsoriasis (Auckland, N.Z.)2025

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study.

Ulrich Mrowietz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.